TMEM62

Across TCGA pan-cancer cohorts, TMEM62 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TMEM62’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TMEM62 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TMEM62 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

CCRCC, LUAD, and COAD are the cancer types where TMEM62 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMEM62 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.529	<.001	7	view →
LUAD	Male	III,IV	+0.496	<.001	7	view →
COAD	Female	All	+0.355	<.001	6	view →
HNSC	Male	II,III,IV	−0.440	.018	3	view →
LSCC	All	All	+0.155	.021	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

TMEM62–CCRCC

Open the CCRCC breakdown →